Medline Updates Customers and Patients on Repair and Replace Program for Recall of Medline Brand Beds, Rails, Mattresses and Accessories
Medline has initiated a recall, market exit and discontinuation of all Medline-brand beds, rails, mattresses and accessories (e.g., pendants, motor boxes) over a potential fire hazard and entrapment risk that may cause patient injury or death, and is updating customers on its repair-and-replace program. Facilities and QA/PV staff using these devices should check inventory, follow the repair/replace instructions and report any related adverse events.
Medline Updates Customers and Patients on Repair and Replace Program for Recall of Medline Brand Beds, Rails, Mattresses and Accessories
Medline has initiated a recall, market exit and discontinuation of all Medline Brand beds, rails, mattresses and accessories (e.g., pendants, motor boxes) because of a potential fire hazard and entrapment risk that could cause patient injury or death, and is now updating customers and patients on its repair and replace program. The source text is truncated after 'As of November 8, 2', so program details and the current scope of affected units are not available here.
Urgent Field Safety Notice for Gelweave Vascular Prosthesis by Vascutek Ltd
BfArM has published an Urgent Field Safety Notice from Vascutek Ltd covering its Gelweave Vascular Prosthesis, with the specific issue, affected lots and required actions set out only in the manufacturer's Advisory Notice, which the listing does not describe. Device users and QA/vigilance teams should read the full notice to establish whether their stock or patients are affected and what corrective action is required.
Urgent Field Safety Notice for LEONI 4 by Löwenstein Medical GmbH & Co. KG
BfArM has published an Urgent Field Safety Notice from Löwenstein Medical GmbH & Co. KG for the LEONI 4 device; the specific hazard, affected units and required corrective actions are only in the manufacturer's Advisory Notice, which was not included in the information provided. Because it is an urgent field safety notice, QA/PV teams with the device in use or supply should review the full Advisory Notice promptly to determine whether action is needed.
Urgent Field Safety Notice for IntelliVue Patient Monitor by Philips Medizin Systeme Böblingen GmbH
BfArM has published an Urgent Field Safety Notice from Philips Medizin Systeme Böblingen GmbH concerning its IntelliVue Patient Monitor. The listing gives no details of the issue or required actions, so users must consult the manufacturer's enclosed Advisory Notice to assess whether their devices are affected.
Urgent Field Safety Notice for guidewires (various) by EPflex Feinwerktechnik GmbH (BfArM field safety notices)
BfArM has published an Urgent Field Safety Notice from EPflex Feinwerktechnik GmbH covering various guidewire (Führungsdraht) devices; the specific issue, affected models and required actions are only in the manufacturer's attached advisory notice and are not stated in the listing. QA/PV and device-vigilance teams should read the full notice to determine whether any affected products are in use or in stock and what corrective actions apply.
Urgent Field Safety Notice for VITROS Chemistry Products A1c Slides by QuidelOrtho (Ortho Clinical Diagnostics Inc)
BfArM has published an Urgent Field Safety Notice from QuidelOrtho (Ortho Clinical Diagnostics) covering VITROS Chemistry Products A1c Slides, an in vitro diagnostic used for HbA1c testing. The input gives no details on the defect, affected lots or required actions, so users should consult the manufacturer's enclosed Advisory Notice for scope and corrective measures.
CBER-Regulated Products with Supporting Documents
FDA CBER has published or updated a listing page titled 'CBER-Regulated Products with Supporting Documents', which collates CBER-regulated biologic products with their associated supporting documents. The source gives no detail on specific products, documents or changes, so the practical significance is limited to its use as a reference resource; review the page directly to identify any relevant updates.
Find product information about medicines
MHRA has a guidance page explaining how to find product information for UK medicines, including patient information leaflets (PILs), summaries of product characteristics (SPCs) and public assessment reports (PARs). The input does not describe any new change, so it is a reference resource for locating authorised product information and assessment reports.
FTC Sues to Block Veterinary Supplies Distributor Covetrus’s $3.5 Billion Acquisition of Rival MWI
The FTC has sued to block Covetrus's $3.5 billion acquisition of rival MWI Veterinary Supply (from Cencora), alleging the deal would merge the two largest US veterinary clinic distributors, which supply veterinary pharmaceuticals, vaccines and clinic consumables, and would raise prices and reduce service quality. It is an antitrust action on veterinary distribution competition, with no direct pharmacovigilance or product-safety implications; its relevance is limited to supply-chain and pricing dynamics for veterinary medicines.
Voltabak; supply difficulty (DKMA)
The Danish Medicines Agency (DKMA) has updated its notice on current supply problems with Voltabak 1 mg/ml eye drops, solution, from Laboratoires Thea S.A.S. The input gives no details on cause, duration or alternatives, so QA/PV and supply-chain teams should check the full DKMA notice for the specifics.
Florida Man Pleads Guilty to $42M Durable Medical Equipment and Cancer Genetic Testing Fraud on Medicare
A Florida man pleaded guilty to a $42 million Medicare fraud scheme involving false claims for durable medical equipment and cancer genetic testing, as well as fraudulently obtaining a PPP loan. It is a DOJ enforcement action relevant to healthcare fraud and compliance, with no direct pharmacovigilance or product safety implications.
Attorney General Raoul Announces Medicaid Fraud Charges In Two Separate Cases
The Illinois Attorney General announced Medicaid fraud charges in two separate cases, as relayed via the HHS OIG enforcement feed. The source gives no details on the defendants, the alleged conduct, or any link to medicines, so its relevance to pharma is unclear, though it shows continued state-level Medicaid fraud enforcement.
Attorneys General Jeff Jackson and Chris Carr Announce North Carolina and Georgia Will Lead National Medicaid Fraud Control Association
The Attorneys General of North Carolina (Jeff Jackson) and Georgia (Chris Carr) have been announced as leaders of the National Medicaid Fraud Control Association. The item is a leadership announcement with no stated new rules or enforcement actions, so it is of limited direct impact but may signal state-level Medicaid fraud enforcement priorities relevant to pharma compliance.
Maryland Behavioral Health Worker Pleads Guilty to Billing D.C. Medicaid for Therapy Sessions That Never Happened
A Maryland behavioral health worker pleaded guilty to billing D.C. Medicaid for therapy sessions that never took place, according to HHS OIG. This is a healthcare fraud enforcement case; the input gives no further details (amounts, sentencing), and it has no direct pharmacovigilance or product-safety implications.
Clarksville Pain Management Clinic and Managers Agree to Pay $1.5 Million to Resolve False Claims Act Allegations Involving Medically Unnecessary Testing
HHS OIG reports that a Clarksville pain management clinic and its managers have agreed to pay $1.5 million to resolve False Claims Act allegations of billing federal healthcare programs for medically unnecessary testing. The notice gives no further detail, but it shows continued enforcement attention on billing and medical-necessity practices at healthcare providers, which is a compliance concern rather than a product safety issue.
Jacksonville Pharmacy Owner and Accountant Indicted in $51 Million Health Care Fraud Scheme
HHS OIG reports that a Jacksonville pharmacy owner and an accountant have been indicted in an alleged $51 million health care fraud scheme. The input gives no further detail on the charges or mechanism, so the item matters mainly as a pharmacy-sector fraud enforcement action; an indictment is an allegation, not a conviction.
Dacarbazine "Lipomed" 500 mg; supply difficulties (DKMA)
DKMA reports current supply problems with Dacarbazine "Lipomed" 500 mg powder for solution for infusion from Lipomed GmbH. The notice gives no further detail in the description, but healthcare providers and supply-chain/QA teams should check availability and consider contingency arrangements for this cytotoxic product.
Methergin; supply difficulty (DKMA)
DKMA reports a supply difficulty for Methergin 0.2 mg/ml solution for injection, as Essential Pharma Limited has ceased marketing the product in Denmark. Methylergometrine is used in obstetric haemorrhage management, so QA/PV and supply-chain teams should check for alternatives and assess any continuity-of-supply implications.
SCRI Oncology Partners Agreed to Pay $249,000 for Allegedly Violating the Civil Monetary Penalties Law by Submitting Claims for Services Provided by an Unlicensed Individual
SCRI Oncology Partners agreed to pay $249,000 to resolve HHS OIG allegations that it violated the Civil Monetary Penalties Law by submitting claims for services provided by an unlicensed individual. The settlement is a reminder that organisations delivering oncology and clinical services need to verify staff licensure and credentialing before billing federal healthcare programs.
Arizona Otolaryngology Consultants Agreed to Pay $42,000 for Allegedly Violating the Civil Monetary Penalties Law by Submitting Claims for Services Performed by a Non-enrolled Provider
HHS OIG announced that Arizona Otolaryngology Consultants agreed to pay $42,000 to resolve allegations that it violated the Civil Monetary Penalties Law by submitting claims for services performed by a provider who was not enrolled in Medicare. The settlement shows that OIG enforces provider enrollment requirements, so billing compliance controls should verify enrollment before claims are submitted.
Medical Devices Bulletin. July-September 2026 (AEMPS)
AEMPS has published its Medical Devices Bulletin for July-September 2026, but the input gives only the title and no details of its contents. Check the bulletin directly for any device safety notices, field safety corrective actions or regulatory updates that may affect vigilance and QA obligations.
Human medicines European public assessment report (EPAR): Qezzaqar, catequentinib, Status: Application withdrawn
EMA has updated the EPAR page for Qezzaqar (catequentinib) to show the marketing authorisation application was withdrawn, so the product will not be authorised in the EU via this application. The input gives no reason for the withdrawal or indication; for PV/QA teams this is mainly informational, with no authorised-product safety or labelling obligations arising.
Human medicines European public assessment report (EPAR): Zybrivo, sintilimab, Status: Opinion
EMA has listed an EPAR entry for Zybrivo (sintilimab) with the status "Opinion", meaning a CHMP opinion on the product has been recorded. The entry gives no indication, outcome or conditions, so check the full EPAR and CHMP documents before planning any PV system, RMP or labelling work.
Human medicines European public assessment report (EPAR): Ruxolitinib Krka, ruxolitinib, Status: Opinion
EMA's CHMP has issued an opinion on Ruxolitinib Krka (ruxolitinib), and the EPAR has been published or updated to reflect it. Ruxolitinib Krka appears to be a generic of the reference product, so the update mainly matters for market access and product information alignment, with no new safety issue indicated in the source.
Human medicines European public assessment report (EPAR): Garzulys, insulin aspart, Status: Opinion
EMA has published an EPAR entry for Garzulys (insulin aspart) with status 'Opinion', meaning the product has reached the CHMP opinion stage of the centralised procedure. The source gives no detail on the outcome or conditions, so check the full EPAR and opinion documents before planning PV, RMP or labelling activities.
Human medicines European public assessment report (EPAR): Fondaparinux sodium Evumed, fondaparinux sodium, Status: Opinion
The EMA has published an EPAR entry for Fondaparinux sodium Evumed (fondaparinux sodium) with status 'Opinion', indicating a CHMP opinion on this product, which appears to be a generic or duplicate of an existing fondaparinux product. The input gives no details on indication, safety findings or conditions, so the full EPAR should be checked for specifics.
Human medicines European public assessment report (EPAR): Donrafylix, insulin aspart, Status: Opinion
EMA has published an EPAR entry for Donrafylix (insulin aspart) with status 'Opinion', meaning the product is at the CHMP opinion stage of the EU marketing authorisation process. The source gives no details on the outcome, indication or whether it is a biosimilar, so check the full EPAR documents before assessing impact on insulin aspart portfolios or PV obligations.
Human medicines European public assessment report (EPAR): Baxfendy, baxdrostat, Status: Opinion
EMA has published an EPAR entry for Baxfendy (baxdrostat) with status 'Opinion', indicating a regulatory opinion on this medicine has been issued; the input does not state the indication or the opinion's outcome. PV and regulatory teams should check the full EPAR and product information for the conditions of use, any risk minimisation measures and the RMP.
Human medicines European public assessment report (EPAR): Aumseqa, Aumolertinib, Status: Opinion
EMA has published an EPAR page for Aumseqa (aumolertinib) with status 'Opinion', indicating the CHMP has adopted an opinion on the product. The input gives no indication, approval wording or conditions, so check the full EPAR and CHMP documents for details before acting on labelling, RMP or PV system implications.
Safety notices for medical devices – October 2026 (JAZMP)
JAZMP (Slovenia) has published its October 2026 batch of field safety notices on its website, covering safety corrective actions for medical devices notified by manufacturers or their authorised representatives. QA/PV and vigilance teams should review the notices for devices they place on the market, distribute or use in Slovenia, and check whether any follow-up action is required.
For pharmaceutical companies; foreign alternative to medicine in supply failure (estradiol, 25 micrograms/24 hours depot patches) (DKMA)
The Danish Medicines Agency (DKMA) has updated the time period for an estradiol 25 micrograms/24 hours transdermal patch on its list of medicines in supply failure. Danish marketing authorisation holders or suppliers can therefore supply a corresponding foreign-market product under section 29(2) of the Danish Medicines Act, so the updated period determines how long that import route applies.
For pharmaceutical companies; foreign alternative to medicine in supply failure (estradiol, 37.5 micrograms/24 hours depot patches) (DKMA)
The Danish Medicines Agency (DKMA) has updated the time period for an estradiol 37.5 micrograms/24 hours transdermal patch on its list of medicines in supply failure, for which the Danish market is to be supplied with an equivalent foreign medicine under section 29(2) of the Danish Medicines Act. Marketing authorisation holders and suppliers should check the updated period when planning imports of a foreign alternative.
Prasugrel Viatris 5 mg; supply difficulty (DKMA)
DKMA reports a current supply problem with Prasugrel Viatris 5 mg film-coated tablets from Viatris ApS in Denmark. The notice gives no cause, duration or alternatives, but prasugrel is an antiplatelet used after acute coronary syndrome, so PV and QA teams may need to monitor availability and the potential impact on patients.
Prasugrel Viatris 10 mg; supply difficulty (DKMA)
The Danish Medicines Agency (DKMA) reports current supply problems with Prasugrel Viatris 10 mg film-coated tablets from Viatris ApS. This matters because prasugrel is an antiplatelet agent, so QA/PV teams may need to monitor availability and possible switching to alternatives; the input gives no details on duration, cause or recommended alternatives.
Frovatriptan "Viatris"; supply difficulties (DKMA)
DKMA reports current supply problems with Frovatriptan "Viatris" 2.5 mg film-coated tablets from Viatris ApS in Denmark. The notice gives no duration, cause or alternatives, but it may affect availability for migraine patients and calls for supply-continuity checks.
Watch it back! Webinar on pilot coordinated assessment for medical devices
The European Commission (DG SANTE) has made available a recording of its webinar on the pilot coordinated assessment for medical devices. The source gives no detail on the pilot's scope or outcomes, so it is mainly useful as background for teams following medical device regulatory processes.
MHRA: services during Microsoft outage
The MHRA reported problems sending and receiving emails during a Microsoft outage, which may delay email correspondence with the agency. The notice gives no further detail, so PV and regulatory teams should check the MHRA's website for current guidance on submissions and contact routes.
VICH GL49: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food producing animals: validation of analytical methods used in residue depletion studies - Revision 2
EMA has published Revision 2 of VICH GL49, the guideline on validating analytical methods used in residue depletion studies for veterinary drugs in food-producing animals. The input does not state what was changed in this revision, so the revised text should be checked directly; the guideline matters to sponsors of veterinary residue studies supporting MRL and withdrawal period determinations.
Draft guideline on veterinary good pharmacovigilance practices (VGVP) - List of medically important (MI) VeDDRA terms
EMA has published a draft guideline under veterinary good pharmacovigilance practices (VGVP) containing a list of medically important VeDDRA terms for veterinary adverse event reporting. The input gives no detail on how the list will be applied, so PV professionals handling veterinary medicines should review the draft and consider commenting during consultation.
Filter this to your countries, subjects and products
Subscribers get this feed filtered to their markets, with impact flags, alerts and an audit trail.
See plans